Compare Keysight Technologies Inc (KEYS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keysight Technologies Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Keysight Technologies Inc trades at $382.98 (market cap $63.79B), while State Street SPDR S&P Biotech ETF trades at $153.81 (market cap $10.11B). The key difference: Keysight Technologies Inc is far larger — about 6.3× State Street SPDR S&P Biotech ETF's market cap, and Keysight Technologies Inc is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Keysight Technologies Inc for 56 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| KEYS | XBI | |
|---|---|---|
Market Cap | $63.79B | $10.11B |
Volume | 1,435,384 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $387.90 | $169.55 |
52-Week Low | $159.49 | $104.99 |
Typical Hold Time | 56 Days | 38 Days |
Enterprise Value | $63.93B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Keysight Technologies (KEYS) trades at $382.61, up 0.29% with a bullish technical signal and strong institutional support. The stock shows robust fundamentals with accelerating earnings, beating estimates for three consecutive quarters, and impressive profitability metrics including 19.14% net income margin and 20.59% ROE. Recent news highlights AI infrastructure demand and 6G development opportunities, positioning the company for continued growth.
KEYS presents a compelling investment case with strong analyst consensus (81% buy ratings) and a $416.63 price target offering 8.9% upside. However, elevated valuation ratios (P/E 50.7, P/S 9.85) and supply chain constraints present near-term risks. The company's leadership in AI testing and 6G technology provides long-term growth catalysts despite current premium pricing.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
